Evidence map›Paper›PMID 38958912›Full record

ArticleRheumatology and therapy2024

Gender Differences in Perceptions of Psoriatic Arthritis Disease Impact, Management, and Physician Interactions: Results from a Global Patient Survey.

Lihi Eder, Pascal Richette, Laura C Coates, Valderilio F Azevedo, Joseph C Cappelleri, Edward P Johnson, Megan Hoang, Jade Moser, Meriem Kessouri

Abstract read
In one paragraph

Article in Rheumatology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lihi EderDivision of Rheumatology, Women's College Research Institute, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-1473-1715
Pascal RichetteAP-HP, Rheumatology Department, Lariboisière Hospital, Paris Cité University, Paris, France.ORCID http://orcid.org/0000-0003-2132-4074
Laura C CoatesNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, UK.ORCID http://orcid.org/0000-0002-4756-663X
Valderilio F AzevedoDepartment of Internal Medicine, Hospital de Clínicas at the Federal University of Paraná, Brazil, Curitiba, Brazil.ORCID http://orcid.org/0000-0002-2346-388X
Joseph C CappelleriStatistical Research and Data Science Center, Pfizer Inc, Groton, CT, USA.ORCID http://orcid.org/0000-0001-9586-0748
Edward P JohnsonThe Harris Poll, Media Communications Research, Rochester, NY, USA.
Megan HoangPfizer Inc, Inflammation and Immunology, New York, NY, USA.ORCID http://orcid.org/0000-0001-6836-3201
Jade MoserThe Harris Poll, Media Communications Research, Rochester, NY, USA.
Meriem KessouriInflammation and Immunology, Pfizer France, 23-25 Avenue du Dr Lannelongue, 75668, Paris, France. meriem.kessourihoceini@pfizer.com.ORCID http://orcid.org/0000-0001-9967-3210

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe evaluated the impact of gender on disease severity, health-related quality of life (HRQoL), treatment management, and patient-healthcare professional (HCP) interactions from the perspectives of patients with psoriatic arthritis (PsA).

methodsData were collected from a global online patient survey conducted by The Harris Poll (November 2, 2017 to March 12, 2018). Eligible patients were aged ≥ 18 years, with a self-reported diagnosis of PsA for > 1 year, had visited a rheumatologist/dermatologist in the past 12 months, and had reported previously using ≥ 1 conventional synthetic or biologic disease-modifying antirheumatic drug. Data were stratified by gender and analyzed descriptively, inferentially by binomial (chi-square) tests, and by multivariate logistic regression models.

resultsData from 1286 patients who participated were included: 52% were female, 48% were male. Varying perceptions of disease severity between males and females were indicated by differences in symptoms leading to a diagnosis of PsA, and in symptoms reported despite treatment; more females than males reported joint tenderness, skin patches/plaques, and enthesitis. More females than males reported a major/moderate impact of PsA on their physical activity and emotional/mental well-being. Reasons for switching medication differed between genders, with more females switching because they perceived their medication to not be effective enough related to their joint symptoms. More females than males were very satisfied with their communication with their rheumatologist and were more likely to discuss the impact of PsA on their daily lives, their treatment satisfaction, and treatment goals with their rheumatologist.

conclusionsPatients' perceptions of the impact of PsA on HRQoL, treatment management, and interactions with HCPs varied between males and females. More females than males reported major/moderate physical and emotional impacts of PsA. When treating patients, it is important for HCPs to consider the potential impact of gender on patients' experience of PsA and its symptoms. Graphical plain language summary available for this article.

Indexed as

Gender differencesGlobal surveyPatient perceptionPatient-reported outcomesPsoriatic arthritis

Identifiers

PMID38958912
PMCPMC11422324

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.